Parabilis Medicines CEO Mathai Mammen, M.D., Ph.D., told Fierce the industry had been in “retreat mode for some time” before its latest rebound. (mesh cube/iStock/Getty Images Plus) Elon Musk's SpaceX ...
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...
In its annual Biotech Beyond Borders report, EY projects growth to continue throughout 2026, fueled primarily by the increased volume and value of M&A and licensing deals. (Techa Tungateja/GettyImages ...
Pierre-Alain Ruffieux, Cytiva’s group executive, bioprocess, discusses completion of the doubling of the company’s liquid ...
The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology and neurology to rare ...
US biotech startup Jellatech has signed a deal with South Korea’s Hugel to develop and commercialise its cell-based human collagen for medical aesthetics and cosmetic products. Jellatech is inching ...
Discover the latest in biotechnology with press releases highlighting innovations, research, and developments driving biotech's future. Stay informed on advancements changing biotech and explore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results